In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials

is an important nosocomial pathogen that causes approximately 500,000 cases of infection (CDI) and 29,000 deaths annually in the United States. Antibiotic use is a major risk factor for CDI because broad-spectrum antimicrobials disrupt the indigenous gut microbiota, decreasing colonization resistanc...

Full description

Saved in:

Bibliographic Details
Published in:	mBio Vol. 11; no. 2
Main Authors:	Selle, Kurt, Fletcher, Joshua R, Tuson, Hannah, Schmitt, Daniel S, McMillan, Lana, Vridhambal, Gowrinarayani S, Rivera, Alissa J, Montgomery, Stephanie A, Fortier, Louis-Charles, Barrangou, Rodolphe, Theriot, Casey M, Ousterout, David G
Format:	Journal Article
Language:	English
Published:	United States American Society for Microbiology 10-03-2020
Subjects:	Animals Bacteriophages - genetics Clostridioides difficile - genetics CRISPR-Associated Proteins - genetics CRISPR-Cas Systems - genetics Enterocolitis, Pseudomembranous - microbiology Enterocolitis, Pseudomembranous - therapy Female Genetic Engineering Male Mice Mice, Inbred C57BL Therapeutics and Prevention CRISPR-Cas lysogeny CRISPR Cas3 Clostridioides difficile phage
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!